Skip to main content

Table 1 Key oncological biologics whose patents either have expired or will expire soon

From: What do oncologists need to know about biosimilar products?

Biologic (brand name) Manufacturer Estimated patent expiry (month and year)
United States Europe
Supportive agents
Filgrastim (Neupogen) Amgen/Roche/Jassen Expired Expired
Pegfilgrastim (Neulasta) Amgen Expired Aug 2017
Epoetin alfa (Emprex/Epogen/Procrit) Amgen/Jassen Expired Expired
Darbepoetin alfa (Aranesp) Amgen May 2024 Jul 2016
Monoclonal antibodies
Trastuzumab (Herceptin) Genentech/Roche Jun 2019 Expired
Rituximab (Rituxan/MabThera) Roche Sep 2016 Expired
Cetuximab (Erbitux) Eli Lilly/Bristol-Myers
Squibb/Merck KgaA
Expired Expired
Bevacizumab (Avastin) Genentech/Roche Jul 2019 Jan 2022